HepaStem therapy moves into phase 2 trials for NASH, ACLF

Promethera Biosciences dosed the first patient in a phase 2a clinical study of HepaStem for patients with late stage nonalcoholic steatohepatitis, according to a press release.
The open-label study will evaluate safety and preliminary efficacy of HepaStem, a novel allogenic cell-based therapy for severe liver diseases including cirrhosis and pre-cirrhosis NASH.
“Today’s announcement has special significance for our company as NASH is increasingly going to be a significant value driver for our company,” John Tchelingerian, PhD, president and CEO of Promethera, said in the

Source link

Related posts

More ‘Buyer Beware’ Warnings for Unregulated Stem Cell Clinics


Time to Expand Age Base for HCV Screening?


Yogurt Consumption Linked to Reduced CRC Adenoma Risk in Men


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy